Fortrea (FTRE) delivered the kind of quarter that supports its return-to-growth story. Adjusted earnings of $0.28 per share beat the $0.24 consensus by 16.7% and grew 133.3% from $0.12 a year ago. Revenue of $691.5 million topped the $670.22 million estimate by 3.2%. Management raised the midpoints of full-year revenue and adjusted EBITDA guidance for the second straight quarter. Even so, the top line still fell 1.4% year over year, and the company cut $558 million from its backlog. That is the central tension: commercial momentum is clearly improving, but the base the recovery is built on just got smaller, and it arrives with the stock trading near its highs.
The quality of the beat deserves some scrutiny. The earnings improvement came largely from cost discipline rather than growth. Direct costs fell to $552.0 million from $578.6 million, SG&A declined modestly, and interest expense eased to $20.2 million from $22.6 million. On a GAAP basis, Fortrea swung to net income of $0.6 million, or $0.01 per share, from a $15.9 million loss. That swing is meaningful, but the profit rested on a $4.2 million tax benefit against a $3.6 million pretax loss. Diluted share count also rose to 101.2 million from 93.8 million. Cash generation was the cleaner positive. Operating cash flow was $60.8 million and free cash flow was $52.5 million, up from $19.9 million in the second quarter, which lifted year-to-date free cash flow to $47.4 million from negative $33.3 million a year earlier. Net DSO improved to 15 days, and net leverage dropped 1.4 turns year over year to 3.9x.
The call preserved a credible growth narrative. Revenue rose 2.0% sequentially, and backlog burn improved to 8.9% from 8.6% in Q2 and 8.2% in Q1. Book-to-bill rebounded to 1.12x from 1.06x, lifting the trailing twelve-month ratio to 1.12x from 1.02x at the end of 2025. Biotech bookings are up nearly double digits this year, and biopharma RFP flow is rising. Fortrea also won a large biopharma outsourcing refresh, though management expects it to convert to awards only in 2028. Top-ten customer concentration fell to 53.5% from 60.0% a year ago. Management's tone shifted from "cautiously optimistic" to "square in the middle of recovery," and it reaffirmed the mid-teens EBITDA margin target as "true north."
Bears have legitimate ammunition, however. The backlog adjustment for inactive and not-to-deliver work was larger than analysts expected and took backlog to $7.3 billion from $7.8 billion. Management said the change has no effect on current guidance. Cancellations and negative amendments were also slightly elevated. Adjusted EBITDA of $58.0 million was up 14.4% year over year, but it slipped from $58.7 million in Q2, and margin dipped to 8.4% from roughly 8.7%. The narrowed guidance implies a softer fourth quarter on both revenue and EBITDA, reflecting fewer working days, a step-up in IT spending and a burn rate expected to ease toward 8.5%. The call indicated that implied Q4 EBITDA sits below Street expectations, and the top of the EBITDA range came down to $218 million from $220 million. Compensation investment remains a roughly 200-basis-point margin headwind. Management offered no 2027 guidance, and the previously flagged Investor Day went unmentioned.
The forward-looking catalysts are real but early. Fortrea closed the Worldwide Clinical Trials early-phase acquisition on October 19, adding more than 570 beds and in-house bioanalytical capacity, and it has already won its first bioanalytical award. Management expects the business to be EBITDA-profitable only in 2027, and the deal adds about 0.25x to leverage. Roughly 40% of the company's debt is variable-rate. Separately, the CFO seat is now formally filled, resolving the uncertainty around the interim arrangement in Q2, and a new China leader has been appointed.
The market setup is more demanding than the surprise implies. Shares closed at $25.88 the day before the report, up 32.1% since the open after the July release. The stock is just 1.1% below a fresh 52-week high of $26.16, about 61% above its September 10 low and roughly 65% above its 200-day moving average. Investor sentiment turned modestly more positive, rising to 0.25 from 0.21. Price trend and momentum readings remain positive while sequential growth is neutral. That pattern fits a stock that has run hard on improving bookings ahead of evidence of sustained revenue growth.
The bottom line is that Fortrea delivered a clean beat, better cash flow, stronger bookings and a second guidance midpoint raise, all of which advance the turnaround thesis. The backlog reset, the sequential margin dip and a softer implied fourth quarter show that the recovery still depends on converting demand into revenue. With shares sitting near their highs, the margin for disappointment has narrowed.